{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:42Z","timestamp":1792784622653,"version":"4.5.0"},"reference-count":70,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2027,8,19]],"date-time":"2027-08-19T00:00:00Z","timestamp":1818633600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"JST SPRING","award":["JPMJSP2110"],"award-info":[{"award-number":["JPMJSP2110"]}]},{"name":"The Graduate Program for Medical Innovation (MIP), Kyoto University","id":[{"id":"https:\/\/ror.org\/02kpeqv85","id-type":"ROR","asserted-by":"crossref"}]},{"name":"JSPS KAKENHI, Japan","award":["JP18H02555"],"award-info":[{"award-number":["JP18H02555"]}]},{"name":"JSPS KAKENHI, Japan","award":["JP20K21252"],"award-info":[{"award-number":["JP20K21252"]}]},{"name":"JSPS KAKENHI, Japan","award":["JP22H02747"],"award-info":[{"award-number":["JP22H02747"]}]},{"name":"JSPS KAKENHI, Japan","award":["JP22K19376"],"award-info":[{"award-number":["JP22K19376"]}]},{"name":"JSPS KAKENHI, Japan","award":["JP24K01628"],"award-info":[{"award-number":["JP24K01628"]}]},{"name":"Drug Discovery Research Promotion Project AMED, Japan","award":["JP20ak0101144"],"award-info":[{"award-number":["JP20ak0101144"]}]},{"name":"JSPS Research Fellowship for Young Scientists from JSPS, Japan","award":["25KJ1588"],"award-info":[{"award-number":["25KJ1588"]}]},{"name":"JST FOREST Program","award":["JPMJFR2167"],"award-info":[{"award-number":["JPMJFR2167"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunogenicity remains a major challenge in antibody therapeutics. Antibodies can be recognized as foreign by immune cells, leading to the induction of antidrug antibodies that ultimately compromise therapeutic efficacy. This response is primarily driven by proteolytic processing within antigen-presenting cells and the subsequent presentation of peptide fragments to T cells via major histocompatibility complex molecules. As mirror-image proteins are expected to exhibit resistance to proteolytic degradation, we have been developing mirror-image VHH antibodies composed entirely of d-amino acids. Previously, we generated a d-VHH antibody with specific binding activity to vascular endothelial growth factor A (VEGF-A) and demonstrated that it did not induce antidrug IgG antibodies in a mouse model. However, this d-VHH antibody did not inhibit the VEGF\u2013VEGF receptor interaction, and the immunological processes leading to the lack of IgG antibody induction had not been experimentally demonstrated. In this study, we constructed a new phage-displayed library to improve the hit rate and enable the efficient chemical synthesis of d-VHH antibodies. Using this library, mirror-image screening against d-VEGF identified new VHH antibody sequences with specific binding. The synthesized d-VHH antibody inhibited the VEGF\u2013VEGF receptor interaction. Next, we investigated the immunogenicity of d-VHH antibody using a conventional l-VHH antibody as a reference. The d-VHH antibody resisted enzymatic degradation and, in a mouse model, did not induce inflammatory cytokine production, T-cell responses, or the formation of antidrug antibodies against the administered antibody. Collectively, these findings highlight the potential of inhibitory d-VHH antibodies as a promising approach for developing low-immunogenic therapeutic antibodies.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00264","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:01:58Z","timestamp":1787198518000},"page":"1845-1856","source":"Crossref","is-referenced-by-count":0,"title":["Identification\nof a Mirror-Image VHH Antibody with\nVEGF-Inhibitory Activity and Characterization of Its Immunogenicity"],"prefix":"10.1021","volume":"37","author":[{"given":"Kayuu","family":"Maeda","sequence":"first","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manrei","family":"Yonemura","sequence":"additional","affiliation":[{"name":"Kyoto Pharmaceutical University , , ,","place":["Kyoto, Japan, 607-8412"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aoki","sequence":"additional","affiliation":[{"name":"Kyoto Pharmaceutical University , , ,","place":["Kyoto, Japan, 607-8412"]},{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaya","family":"Imahori","sequence":"additional","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6664-8117","authenticated-orcid":true,"given":"Naoya","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Kyoto Pharmaceutical University , , ,","place":["Kyoto, Japan, 607-8412"]},{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Oka","sequence":"additional","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8507"]},{"name":"Fujita Health University , , , ,","place":["Toyoake, Aichi, Japan, 470-1192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoji","family":"Morise","sequence":"additional","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuaki","family":"Higashi","sequence":"additional","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8507"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-2539","authenticated-orcid":true,"given":"Shinya","family":"Oishi","sequence":"additional","affiliation":[{"name":"Kyoto Pharmaceutical University , , ,","place":["Kyoto, Japan, 607-8412"]},{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8487-6485","authenticated-orcid":true,"given":"Motohiro","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8507"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"15","key":"2026091607071587500_cit1","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","article-title":"Designing antibodies as therapeutics","volume":"185","author":"Carter","year":"2022","journal-title":"Cell"},{"issue":"10","key":"2026091607071587500_cit2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals:\nthe past,\npresent and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"2026091607071587500_cit3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory,\nantibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J. Immunother.\nCancer"},{"issue":"14","key":"2026091607071587500_cit4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug\nantibodies against adalimumab\nand association with disease activity and treatment failure during\nlong-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"2026091607071587500_cit5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of\nanti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"2026091607071587500_cit6","doi-asserted-by":"publisher","first-page":"1995929","DOI":"10.1080\/19420862.2021.1995929","article-title":"The impact\nof immunogenicity on therapeutic\nantibody pharmacokinetics: A preclinical evaluation of the effect\nof immune complex formation and antibody effector function on clearance","volume":"13","author":"Opolka-Hoffmann","year":"2021","journal-title":"mAbs"},{"issue":"4","key":"2026091607071587500_cit7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/art.30209","article-title":"Venous and Arterial\nThromboembolic Events in Adalimumab-Treated Patients with Antiadalimumab\nAntibodies: A Case Series and Cohort Study","volume":"63","author":"Korswagen","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"3","key":"2026091607071587500_cit8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/BOR.0b013e3283521c4e","article-title":"Immunogenicity of biological therapeutics:\nfrom assay to patient","volume":"24","author":"Krieckaert","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"issue":"4","key":"2026091607071587500_cit9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety\nand side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat.\nRev. Drug Discovery"},{"issue":"12","key":"2026091607071587500_cit10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors:\nimplications for rheumatoid arthritis treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"2026091607071587500_cit11","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.molmed.2021.08.003","article-title":"Secondary failure: immune responses\nto approved protein therapeutics","volume":"27","author":"Lagasse\u0301","year":"2021","journal-title":"Trends Mol.\nMed."},{"issue":"2","key":"2026091607071587500_cit12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design:\nApproaches to minimize immunogenicity\nof monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"issue":"12","key":"2026091607071587500_cit13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","article-title":"Immunogenicity risk\nassessment and mitigation for engineered\nantibody and protein therapeutics","volume":"23","author":"Carter","year":"2024","journal-title":"Nat. Rev.\nDrug Discovery"},{"key":"2026091607071587500_cit14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies:\nNatural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev.\nBiochem."},{"issue":"4","key":"2026091607071587500_cit15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"HERCULES Investigators\nCaplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"2026091607071587500_cit16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s11671-025-04200-2","article-title":"Trends in\nnanobody technology in industrialization","volume":"20","author":"Wu","year":"2025","journal-title":"Discover\nNano"},{"issue":"1","key":"2026091607071587500_cit17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of\nozoralizumab, an anti-TNF\u03b1\nNANOBODY\u00ae compound, in patients with rheumatoid arthritis: 52-week\nresults from the OHZORA and NATSUZORA trials","volume":"25","author":"Takeuchi","year":"2023","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"2026091607071587500_cit18","doi-asserted-by":"publisher","first-page":"2324836","DOI":"10.1080\/19420862.2024.2324836","article-title":"T and B cell\nepitope analysis for\nthe immunogenicity evaluation and mitigation of antibody-based therapeutics","volume":"16","author":"Sun","year":"2024","journal-title":"mAbs"},{"issue":"2","key":"2026091607071587500_cit19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-Drug\nAntibody Response to Therapeutic Antibodies and Potential Mitigation\nStrategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"issue":"51","key":"2026091607071587500_cit20","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1021\/bi060986a","article-title":"Construction of\nmodified ribosomes for incorporation of d-amino acids into\nproteins","volume":"45","author":"Dedkova","year":"2006","journal-title":"Biochemistry"},{"issue":"4","key":"2026091607071587500_cit21","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202200537","article-title":"P. D-Peptide\nand D-Protein Technology: Recent Advances,\nChallenges, and Opportunities","volume":"24","author":"Lander","year":"2023","journal-title":"ChemBioChem"},{"issue":"4","key":"2026091607071587500_cit22","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1021\/acschembio.5b01006","article-title":"A Potent D-Protein\nAntagonist of\nVEGF-A Is Nonimmunogenic, Metabolically Stable, and Longer-Circulating\nin Vivo","volume":"11","author":"Uppalapati","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"2026091607071587500_cit23","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.chempr.2024.06.004","article-title":"Mirror-Image\nProtein and Peptide\nDrug Discovery through Mirror-Image Phage Display","volume":"10","author":"Qi","year":"2024","journal-title":"Chem"},{"issue":"6","key":"2026091607071587500_cit24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41570-023-00493-y","article-title":"Synthesis\nand applications of mirror-image proteins","volume":"7","author":"Harrison","year":"2023","journal-title":"Nat.\nRev. Chem."},{"issue":"1","key":"2026091607071587500_cit25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41467-024-45634-z","article-title":"Mirror-Image Ligand\nDiscovery Enabled by Single-Shot Fast-Flow Synthesis of D-Proteins","volume":"15","author":"Callahan","year":"2024","journal-title":"Nat. Commun."},{"issue":"5257","key":"2026091607071587500_cit26","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1126\/science.271.5257.1854","article-title":"Identification of\nD-peptide ligands\nthrough mirror-image phage display","volume":"271","author":"Schumacher","year":"1996","journal-title":"Science"},{"issue":"11","key":"2026091607071587500_cit27","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1021\/acs.bioconjchem.3c00372","article-title":"Mirror-Image Single-Domain\nAntibody for a Novel Nonimmunogenic Drug Scaffold","volume":"34","author":"Aoki","year":"2023","journal-title":"Bioconjugate Chem."},{"issue":"5","key":"2026091607071587500_cit28","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1021\/acschembio.4c00197","article-title":"Engineering\na Low-Immunogenic Mirror-Image\nVHH against Vascular Endothelial Growth Factor","volume":"19","author":"Aoki","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"2026091607071587500_cit29","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1021\/acs.bioconjchem.4c00204","article-title":"Chemical synthesis\nof interleukin-6 for mirror-image screening","volume":"35","author":"Aoki","year":"2024","journal-title":"Bioconjugate Chem."},{"issue":"35","key":"2026091607071587500_cit30","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.1002\/anie.201103237","article-title":"Total chemical synthesis\nof biologically active vascular\nendothelial growth factor","volume":"50","author":"Mandal","year":"2011","journal-title":"Angew. Chem., Int.\nEd."},{"issue":"11","key":"2026091607071587500_cit31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial\ngrowth factor A","volume":"24","author":"Pe\u0301rez-Gutie\u0301rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026091607071587500_cit32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev.med.58.061705.145635","article-title":"Targeting VEGF-A to\ntreat cancer and age-related macular degeneration","volume":"58","author":"Ferrara","year":"2007","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"2026091607071587500_cit33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41594-018-0028-6","article-title":"Yeast Surface Display\nPlatform for Rapid Discovery of Conformationally Selective Nanobodies","volume":"25","author":"McMahon","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"2026091607071587500_cit34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jmb.2004.05.051","article-title":"High-affinity human\nantibodies from\nphage-displayed synthetic Fab libraries with a single framework scaffold","volume":"340","author":"Lee","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"1","key":"2026091607071587500_cit35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jb\/mvad077","article-title":"Construction of a T7\nphage random peptide library by combining seamless cloning with in\nvitro translation","volume":"175","author":"Higashi","year":"2023","journal-title":"J. Biochem."},{"issue":"126","key":"2026091607071587500_cit36","doi-asserted-by":"publisher","first-page":"56144","DOI":"10.3791\/56144","article-title":"Synthesis\nof Infectious Bacteriophages in an E. coli-based Cell-free Expression\nSystem","author":"Rustad","year":"2017","journal-title":"J. Vis. Exp."},{"issue":"6","key":"2026091607071587500_cit37","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gr.849004","article-title":"WebLogo: A sequence logo generator","volume":"14","author":"Crooks","year":"2004","journal-title":"Genome Res."},{"issue":"8","key":"2026091607071587500_cit38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cbic.200300631","article-title":"Selection\nof D-Amino-Acid Peptides That Bind to Alzheimer\u2019s Disease Amyloid\nPeptide A\u03b21\u201342 by Mirror Image Phage Display","volume":"4","author":"Wiesehan","year":"2003","journal-title":"ChemBioChem"},{"issue":"21","key":"2026091607071587500_cit39","doi-asserted-by":"publisher","first-page":"11235","DOI":"10.1128\/JVI.01339-10","article-title":"Design of a Potent\nD-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance","volume":"84","author":"Welch","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"2026091607071587500_cit40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0092-8674(00)80066-5","article-title":"Inhibiting\nHIV-1 Entry: Discovery of D-Peptide Inhibitors That Target the Gp41\nCoiled-Coil Pocket","volume":"99","author":"Eckert","year":"1999","journal-title":"Cell"},{"issue":"32","key":"2026091607071587500_cit41","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1073\/pnas.1008930107","article-title":"D-Peptide\nInhibitors of the P53-MDM2 Interaction for Targeted Molecular\nTherapy of Malignant Neoplasms","volume":"107","author":"Liu","year":"2010","journal-title":"Proc. Natl.\nAcad. Sci. U. S. A."},{"issue":"21","key":"2026091607071587500_cit42","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1002\/anie.201000329","article-title":"A Left-Handed Solution\nto Peptide Inhibition of the P53-MDM2 Interaction","volume":"49","author":"Liu","year":"2010","journal-title":"Angew. Chem., Int. Ed."},{"issue":"40","key":"2026091607071587500_cit43","doi-asserted-by":"publisher","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking\nof the PD-1\/PD-L1 Interaction by a D-Peptide Antagonist for Cancer\nImmunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angew. Chem., Int. Ed."},{"issue":"16","key":"2026091607071587500_cit44","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/cbic.201900355","article-title":"Protein Chemical Synthesis\nCombined with Mirror-Image Phage Display Yields D-Peptide EGF Ligands\nThat Block the EGF-EGFR Interaction","volume":"20","author":"Di\u0301az-Perlas","year":"2019","journal-title":"ChemBioChem"},{"issue":"35","key":"2026091607071587500_cit45","doi-asserted-by":"publisher","first-page":"15114","DOI":"10.1002\/anie.202002783","article-title":"A Novel D-Peptide Identified by Mirror-Image Phage Display Blocks\nTIGIT\/PVR for Cancer Immunotherapy","volume":"59","author":"Zhou","year":"2020","journal-title":"Angew. Chem.,\nInt. Ed."},{"issue":"8","key":"2026091607071587500_cit46","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1021\/acs.bioconjchem.7b00326","article-title":"Novel Strategy Utilizing Extracellular\nCysteine-Rich Domain of Membrane Receptor for Constructing D-Peptide\nMediated Targeted Drug Delivery Systems: A Case Study on Fn14","volume":"28","author":"Li","year":"2017","journal-title":"Bioconjugate Chem."},{"issue":"21","key":"2026091607071587500_cit47","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/cbic.202100287","article-title":"Potent\nTau Aggregation Inhibitor\nD-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage\nDisplay","volume":"22","author":"Malhis","year":"2021","journal-title":"ChemBioChem"},{"issue":"1","key":"2026091607071587500_cit48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241157","article-title":"Development of an\nOrally-Administrable Tumor Vasculature-Targeting\nTherapeutic Using Annexin A1-Binding D-Peptides","volume":"16","author":"Nonaka","year":"2021","journal-title":"PLoS One"},{"key":"2026091607071587500_cit49","doi-asserted-by":"crossref","unstructured":"Liang, Y.; Luo, H.; Li, X.; Liu, S.; Habib, A.; Liu, B.; Huang, J.; Wang, J.; Yi, H.; Hu, B.; et al.\n          PD-L1 Targeted\nPeptide\nDemonstrates Potent Antitumor and Immunomodulatory Activity in Cancer\nImmunotherapy.\n          Front. Immunol.\n          2024\n          15\n          1367040\n          10.3389\/fimmu.2024.1367040.","DOI":"10.3389\/fimmu.2024.1367040"},{"issue":"1","key":"2026091607071587500_cit50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41531-025-01132-7","article-title":"Direct\nDisassembly of \u03b1-Syn Preformed Fibrils into \u03b1-Syn Monomers\nby an All-D-Peptide","volume":"11","author":"Sevenich","year":"2025","journal-title":"NPJ Parkinsons Dis."},{"issue":"11","key":"2026091607071587500_cit51","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1021\/acschembio.5c00726","article-title":"Chemokine-Binding\nAll-D-CLIPS Peptides Identified Using Mirror-Image Phage Display","volume":"20","author":"Denisov","year":"2025","journal-title":"ACS Chem. Biol."},{"issue":"26","key":"2026091607071587500_cit52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426554122","article-title":"De Novo Design of D-Peptide Ligands: Application to Influenza Virus\nHemagglutinin","volume":"122","author":"Juraszek","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S.\nA."},{"issue":"37","key":"2026091607071587500_cit53","doi-asserted-by":"publisher","first-page":"14779","DOI":"10.1073\/pnas.1210483109","article-title":"Chemical synthesis and X-ray structure\nof a heterochiral {D-protein antagonist plus vascular endothelial\ngrowth factor} protein complex by racemic crystallography","volume":"109","author":"Mandal","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"2026091607071587500_cit54","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acschembio.1c00017","article-title":"A Non-Immunogenic Bivalent D-Protein Potently Inhibits\nRetinal Vascularization and Tumor Growth","volume":"16","author":"Marinec","year":"2021","journal-title":"ACS\nChem. Biol."},{"issue":"11","key":"2026091607071587500_cit55","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1021\/acsmedchemlett.3c00342","article-title":"Design and Synthesis\nof Monobody\nVariants with Low Immunogenicity","volume":"14","author":"Iwamoto","year":"2023","journal-title":"ACS Med. Chem.\nLett."},{"issue":"1","key":"2026091607071587500_cit56","doi-asserted-by":"publisher","first-page":"10723","DOI":"10.1038\/s41467-024-54902-x","article-title":"Generating a mirror-image monobody targeting MCP-1\nvia TRAP display and chemical protein synthesis","volume":"15","author":"Hayashi","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"2026091607071587500_cit57","doi-asserted-by":"publisher","first-page":"10724","DOI":"10.1038\/s41467-024-54901-y","article-title":"Development\nof Mirror-Image\nMonobodies Targeting the Oncogenic BCR::ABL1 Kinase","volume":"15","author":"Schmidt","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"2026091607071587500_cit58","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.1021\/jacsau.5c01181","article-title":"Discovery of D-miniprotein Inhibitors of PD-1\/PD-L1\nInteraction via Mirror-Image Phage Display against Synthetic d-PD-1","volume":"5","author":"Zhou","year":"2025","journal-title":"JACS Au"},{"issue":"1","key":"2026091607071587500_cit59","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1038\/s41467-025-59295-z","article-title":"Oral PRI-002 Treatment\nin Patients with MCI or Mild\nAD: A Randomized, Double-Blind Phase 1b Trial","volume":"16","author":"Kutzsche","year":"2025","journal-title":"Nat. Commun."},{"key":"2026091607071587500_cit60","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12001","article-title":"Safety and Pharmacokinetics\nof the Orally Available Antiprionic Compound PRI-002: A Single and\nMultiple Ascending Dose Phase I Study","volume":"6","author":"Kutzsche","year":"2020","journal-title":"Alzheimers\nDement. (N.Y.)"},{"issue":"36","key":"2026091607071587500_cit61","doi-asserted-by":"publisher","first-page":"22436","DOI":"10.1073\/pnas.2009700117","article-title":"Prevention and Treatment\nof SHIVAD8 Infection in Rhesus\nMacaques by a Potent D-Peptide HIV Entry Inhibitor","volume":"117","author":"Nishimura","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"2026091607071587500_cit62","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1021\/acs.molpharmaceut.7b01004","article-title":"Pharmacokinetic\nand Chemical Synthesis Optimization of a Potent D-Peptide HIV Entry\nInhibitor Suitable for Extended-Release Delivery","volume":"15","author":"Redman","year":"2018","journal-title":"Mol. Pharmaceutics"},{"key":"2026091607071587500_cit63","doi-asserted-by":"publisher","first-page":"1647230","DOI":"10.3389\/fimmu.2025.1647230","article-title":"Comparative\nanalysis of CDR3 length-dependent\npatterns in VHHs","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"2026091607071587500_cit64","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34317","article-title":"Synthetic Single Domain\nAntibodies for the\nConformational Trapping of Membrane Proteins","volume":"7","author":"Zimmermann","year":"2018","journal-title":"Elife"},{"issue":"1","key":"2026091607071587500_cit65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/antib11010010","article-title":"Construction of a Humanized\nArtificial\nVHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics","volume":"11","author":"Murakami","year":"2022","journal-title":"Antibodies"},{"issue":"3","key":"2026091607071587500_cit66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity\nof humanized and fully human antibodies: Residual immunogenicity resides\nin the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"issue":"10","key":"2026091607071587500_cit67","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.tibs.2019.04.004","article-title":"Drug-Target Association\nKinetics in Drug Discovery","volume":"44","author":"IJzerman","year":"2019","journal-title":"Trends Biochem.\nSci."},{"issue":"7","key":"2026091607071587500_cit68","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1248\/cpb.38.1961","article-title":"Studies on the Optimal\nImmunization\nSchedule of Experimental Animals. V. The Effects of the Route of Injection,\nthe Content of Mycobacteria in Freund\u2019s Adjuvant and the Emulsifying\nAntigen","volume":"38","author":"Hu","year":"1990","journal-title":"Chem. Pharm. Bull."},{"issue":"3","key":"2026091607071587500_cit69","first-page":"467","article-title":"Murine Immune Response\nto HIV-1 P24 Core Protein Following Subcutaneous, Intraperitoneal\nand Intravenous Immunization","volume":"74","author":"Fyfe","year":"1991","journal-title":"Immunology"},{"issue":"1","key":"2026091607071587500_cit70","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/jps.23794","article-title":"Recombinant\nMurine Growth Hormone Particles Are More Immunogenic with Intravenous\nthan Subcutaneous Administration","volume":"103","author":"Christie","year":"2014","journal-title":"J. Pharm.\nSci."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00264","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/9\/1845\/66887637\/acs.bioconjchem.6c00264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/9\/1845\/66887637\/acs.bioconjchem.6c00264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:49:32Z","timestamp":1789559372000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/9\/1845\/5277254\/Identification-of-a-Mirror-Image-VHH-Antibody-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00264","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}